Flash Therapeutics

📍 Toulouse, France🗓 Founded 2018👥 48 employees💰 Last funded Nov 2016
Biotechnology Research🌐 flashtherapeutics.com
Website LinkedIn
Flash Therapeutics is a gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform and bioproduction technologies. The Company is built around the Vectalys lentiviral platform, which includes its patented non-integrative LentiFlash® technology, and integrative lentiviral vectors. By providing efficient, transient and short-term RNA delivery technology, LentiFlash® is suitable for gene editing and other advanced therapeutic approaches. When stable DNA expression is needed (e.g. immunotherapy such as CAR T cells), integrative lentiviral vectors will be the delivery method of choice. Both technologies benefit from novel production and purification processes developed and continually optimized since 2005. Flash Therapeutics was established in 2018 through the merger of FlashCell, a privately held company developing LentiFlash®, based RNA therapeutics; and Vectalys, a leading privately held 13-year old lentiviral vector manufacturer.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Flash Therapeutics?
Flash Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Flash Therapeutics last raise funding?
The most recent investment in Flash Therapeutics recorded on gritt.io was in November 2016.
When was Flash Therapeutics founded?
Flash Therapeutics was founded in 2018.
What industry is Flash Therapeutics in?
Flash Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Flash Therapeutics based?
Flash Therapeutics is headquartered in Toulouse, France.